2. Others
  3. Others
  4. MDL 72527

MDL 72527 is a potent polyamine oxidase (PAO) inhibitor. MDL 72527 shows a lysosomotropic effect. MDL 72527 shows neuroprotective effects.

For research use only. We do not sell to patients.

MDL 72527 Chemical Structure

MDL 72527 Chemical Structure

CAS No. : 93565-01-6

Size Price Stock Quantity
1 mg USD 40 In-stock
5 mg USD 100 In-stock
10 mg USD 160 In-stock
25 mg USD 320 In-stock
50 mg USD 520 In-stock
100 mg USD 830 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of MDL 72527:

MDL 72527 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MDL 72527 is a potent polyamine oxidase (PAO) inhibitor. MDL 72527 shows a lysosomotropic effect. MDL 72527 shows neuroprotective effects[1][2].

IC50 & Target

polyamine oxidase (PAO)[1]
In Vitro

MDL 72527 (300 µM; 24 h) shows evident morphological changes with the appearance of a large number of lysosomes and numerous cytoplasmic vacuoles in M14 WT cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MDL 72527 Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: M14 cells
Concentration: 300 µM
Incubation Time: 24 h
Result: Showed no significant effect on cell survival of melanoma cells.
In Vivo

MDL 72527 (100 mg/kg; i.p.; once) shows neuroprotective against neuronal cell damage after temporary focal cerebral ischemia[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 250-300 g, Male spontaneously hypertensive rats (SHRs)[1]
Dosage: 100 mg/kg
Administration: I.p.; after the induction of ischemia
Result: Significantly reduced meanarterial blood pressure, changed the brain edema formation from 85.7 ± 0.3 to 84.5 ± 0.9% in cortex and from 79.9 ± 1.7 to 78.4 ± 2.0% in subcortex (difference not significant), reduced ischemic injury volume by 22% in the cortex and 17% in the subcortex.
Molecular Weight

265.22

Formula

C12H22Cl2N2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C=C=CCNCCCCNCC=C=C.[H]Cl.[H]Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (377.05 mM; Need ultrasonic)

DMSO : 12.5 mg/mL (47.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7705 mL 18.8523 mL 37.7045 mL
5 mM 0.7541 mL 3.7705 mL 7.5409 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (4.71 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 1.25 mg/mL (4.71 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  Saline

    Solubility: 50 mg/mL (188.52 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 3.7705 mL 18.8523 mL 37.7045 mL 94.2614 mL
5 mM 0.7541 mL 3.7705 mL 7.5409 mL 18.8523 mL
10 mM 0.3770 mL 1.8852 mL 3.7705 mL 9.4261 mL
15 mM 0.2514 mL 1.2568 mL 2.5136 mL 6.2841 mL
20 mM 0.1885 mL 0.9426 mL 1.8852 mL 4.7131 mL
25 mM 0.1508 mL 0.7541 mL 1.5082 mL 3.7705 mL
30 mM 0.1257 mL 0.6284 mL 1.2568 mL 3.1420 mL
40 mM 0.0943 mL 0.4713 mL 0.9426 mL 2.3565 mL
H2O 50 mM 0.0754 mL 0.3770 mL 0.7541 mL 1.8852 mL
60 mM 0.0628 mL 0.3142 mL 0.6284 mL 1.5710 mL
80 mM 0.0471 mL 0.2357 mL 0.4713 mL 1.1783 mL
100 mM 0.0377 mL 0.1885 mL 0.3770 mL 0.9426 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MDL 72527 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MDL 7252793565-01-6MDL72527MDL-72527OthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MDL 72527
Cat. No.:
HY-100621
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.